What this means
This trial plans to compare three forms of omega-3 fats with an olive oil placebo. It will check immune signals and inflammation over time, but no results are posted yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 75 and over
- Where
- Not listed
The science
- Registered title
- Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE)
- Trial ID
- NCT06666101 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Polyvascular Disease
- What is tested
- Long chain polyunsaturated Omega-3, Placebo
- Sponsor
- Université Libre de Bruxelles
- Ages
- 75 Years to no maximum
- Dates
- First posted Oct 30, 2024 · updated Oct 30, 2024
Registry summary
The objectives is to evaluate the effect of omega-3 fatty acids in old participants with polyvascular disease on immune parameters and inflammatory mediators at different times. Three modalities of administration of omega-3 will be compared with a placebo (olive oil): predominant EPA (Eicosapentaenoic acid), predominant DHA (doxosahexaenoic acid), and combinaison of both. This study will measure the level of omega3 fatty acids in this population 4 hours after taking, on the 7th day, on the 21th day of administration and 1 month after administration.